PMC

AR and SOD2 co-localize with C5b-9 in glomeruli of MN patient biopsies. Confocal images of a renal biopsy specimen from MN. (A, B, D, and E) Double IF staining for AR (A), SOD2 (D), and C5b-9 (B and E). Merged images are reported in C and F and in p1 and p2. Both AR and SOD2 co-localize in immune deposits. Magnification, ×630.

AR and SOD2 co-localize with IgG4 in glomeruli of MN patient biopsies. (A, B, D, and E) Confocal images of a renal biopsy specimen from a patient with MN. Double IF staining was evaluated for AR (A), SOD2 (D) and IgG₄ (B and E). Merged images are reported in C and F and in p1 and p2. Both AR and SOD2 were co-localized with IgG₄ along the capillary walls. Magnification, ×630.

In vitro oxidation modifies AR and SOD2 expression on plasma membrane. (A through C) Western blot (A), corresponding bar graph (B; ■, AR; □, SOD2) and IF staining (C) for AR or SOD2 upon H₂O₂ treatment. H₂O₂ treatment increased SOD2 expression at 24 and 48 hours, whereas AR was only slightly affected. IF on nonpermeabilized podocytes confirmed Western blot results. Magnification, ×630.

SOD2 is present in GBM and on podocyte plasma membrane. (A and B) SOD2 was detected in electron-dense immune deposits within the GBM (arrows) as shown by several scattered gold particles. (C and D) SOD2 was also observed in the cytoplasm and on plasma membrane of podocyte bodies (Po). (F) Blank sample omitting specific primary antibody was totally negative (see also Supplemental Figure 5, B, D, and F), EN, endothelium; n, podocyte nucleus. Magnifications: ×8900 in A; ×44,000 in B and C; ×71,000 in D; ×51,000 in E; ×36,000 F.

Glomerular eluates from MN patients contain antibodies against AR and SOD2. (A) Glomeruli showed presence of specific IgG₄ antibodies against AR and SOD2. IgGs were also present at a lower titer. Controls were incubated with human serum albumin (HSA) instead of glomerular eluates. (B) Corresponding bar graph shows dot-spot OD (in arbitrary units) for anti-AR (■) and anti-SOD2 (□) specific IgG₄. (C) Competition experiment using the same glomerular eluates as in A and increasing amount of r-AR and r-SOD2 from 5 to 15 ng.

AR is present in GBM and in subepithelial immune deposits. (A and B) AR is present in GBM as shown by several scattered gold particles in the context of electron-dense subepithelial immune deposits (arrows). (C through E) AR was also observed in the cytoplasm and the plasma membrane of podocyte bodies (Po). (E) AR is not expressed at the nuclear (N) level; instead, AR is present in the cytoplasm as indicated by arrows. (F) Blank sample lacking primary antibody was totally negative (see also Supplemental Figure 5, A, C, and E). EN, endothelium. Magnifications: ×8900 in A; ×56,000 in B, D, and E; ×36,000 in C; ×44,000 in F.

Glomerular eluates from other pathologies do not contain antibodies against AR or SOD2. Dot blot of eluates from microdissected glomeruli of a normal kidney (N) and patients (n = 7) with other glomerulonephritis implying IgG deposition in glomeruli: Systemic lupus nephritis (SLE; n = 5) and membranoproliferative glomerulonephritis (MPGN; n = 2). For comparison, two patients with MN were displayed. Anti-AR and anti-SOD IgG₄ was determined as described in the Concise Methods section. Total IgG titer was determined with dot blot to nonsaturated nitrocellulose membrane, and proteins were revealed with biotinylated anti-human IgG.

Circulating anti-AR and anti-SOD2 antibodies are present in the sera of MN patients and completely absent in FSGS. (A and C) MN sera (n = 24, first two rows) screened for the presence of autoantibodies were positive for both anti-AR (A) and anti-SOD2 (C) IgG₄. Intensity was mild or absent in normal sera (n = 24, bottom rows) and completely absent in FSGS (NS). St., calibration curve. (B and D) Corresponding dot graphs plotting OD for both anti-AR (B) and anti-SOD2 (D) IgG₄. Nonparametric statistical tests (Mann-Whitney U test) showed a statistical difference between MN and normal sera (N) in all cases (P < 0.01 for anti-AR and P < 0.001 for anti-SOD IgG₄; the difference between MN and FSGS was P < 0.001 in all cases).

Glomerular eluates from MN patients contain antibodies against podocyte antigens. Podocyte extracts were separated by electrophoresis in reducing (a through e) and nonreducing (f through h) conditions and were studied for reactivity with eluates from microdissected glomeruli. Thirty micrograms of protein was used for the analysis: Part was analyzed with silver stain (a and f), and part was incubated with glomerular eluates from patients with MN and then developed with anti-IgG₄ (b and g). Eight antigens were recognized in reducing conditions and characterized by mass spectrometry as AR, SOD, and vimentin. Three more bands with a molecular weight of 200, 170, and 155 kD were detected in nonreducing conditions. (c and h) Control lines for Western blot in which glomerular eluates were omitted. (d) Western blot with anti-AR antibody. (e) Western blot with SOD2 antibodies.

AR and SOD2 are expressed in renal biopsies of MN patients. (A through N) Representative images of renal biopsy specimens from normal patients (A through C), and patients with MN (D through F), MCD (G through I), and MN secondary to neoplasia (L through N) stained for synaptopodin (A, D, G, and L), AR (B, E, H, and M), or SOD2 (C, F, I, and N). AR and SOD2 staining is absent in tissues from normal individuals normal and from patients with MCD and only very weakly expressed in tissues from patients with MN secondary to neoplasia, whereas a marked glomerular staining for both proteins is evident in patients with MN. Synaptopodin is included to highlight glomerular structures. Bar = 200 μ. (O and P) Morphometric results of glomerular expression of AR and SOD2 in patients with MN. Bar graph shows glomerular expression of AR (■) and SOD2 (□), as measured by morphometric analysis on tissues from studied cases. Results are expressed as percentage of the positive area for each considered antibody on total glomerular area. The protein expression for both was increased in patients with MN, with high statistical significance (P < 0.001) when compared with control patients with a higher expression of AR in all considered glomeruli. Magnification, ×400.

Sera of MN patients show presence of antibodies against podocyte proteins. (A through C) 2D electrophoresis analysis of podocyte membrane extracts and Western blot analysis of MN serum for anti-podocyte antibodies. (A) Representative 2D map of podocyte membrane extracts stained by colloidal Coomassie. Numbers correspond to identified proteins as displayed in ; spots 1, 2, 3, and 4 correspond to SOD2, and spots 13, 14, and 15 correspond to AR. (B and C) Western blot analysis of MN serum for anti-podocyte antibodies. Sera of patients with MN were largely positive for SOD2 (B and C); only a few were positive for AR (C). Representative normal sera (n = 10) run in parallel to MN samples were negative and have been reported as control. (D through I) Expression of AR and SOD2 on cultured podocytes. Nonpermeabilized human podocyte cell line stained for AR (D) or SOD2 (G) and MN sera (10% in medium) incubated with cells (E and H). (F and I) Merged images. Arrows in merged images indicate the coexpression of AR or SOD2 with MN IgG. Magnification, ×630.